Shares of Sagent Pharmaceuticals (SGNT) Sees Large Inflow of Net Money Flow

Sagent Pharmaceuticals (SGNT) : The money flow analysis of Sagent Pharmaceuticals (SGNT) indicates a $7.37 million of outflow was on downticks, whereas, the investors on Tuesday gobbled up stocks worth $14.76 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 2 and so was the total money flow at $7.39 million. A solid up-down ratio of 24.22 in block trades indicates that the investors are accumulating the stock on weakness. The bulls lapped up $8.01 million worth of block trades on upticks. Only $0.33 million worth of the stock exchanged hands on downticks. The money flow was $7.68 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Sagent Pharmaceuticals (SGNT), pushing it down by -0.09% for the day. The stock slid $0.02 and traded at $21.63 during the day. Nonetheless, the stock is 39.55% over the previous weeks close.


The company Insiders own 30.1% of Sagent Pharmaceuticals shares according to the proxy statements. Institutional Investors own 99.66% of Sagent Pharmaceuticals shares.

Shares of Sagent Pharmaceuticals, Inc. rose by 45.93% in the last five trading days and 54.23% for the last 4 weeks. Sagent Pharmaceuticals, Inc. is up 77.91% in the last 3-month period. Year-to-Date the stock performance stands at 36.2%.

Sagent Pharmaceuticals (NASDAQ:SGNT): stock turned positive on Tuesday. Though the stock opened at $21.66, the bulls momentum made the stock top out at $21.73 level for the day. The stock recorded a low of $21.61 and closed the trading day at $21.67, in the green by 0.09%. The total traded volume for the day was 4,201,033. The stock had closed at $21.65 in the previous days trading.

Sagent Pharmaceuticals, Inc. (Sagent), formerly Sagent Holding Co., is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled, ready-to-use syringes, medical devices and premix bags. As of October 31, 2010, Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides), which is an Indian manufacturer of finished pharmaceutical products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.